None of the above Companies mentioned are like Patrys. They have different cell targets , mainly on the surface of cells and not inside the Cell Necleus like Patrys antibodies.

Patrys’ deoxymab platform is based on unique, proprietary antibodies

Seek out cancer cells, wherever they are in the body

Naturally get inside cells and the cell nucleus

Cross the blood-brain barrier (BBB)

Inhibit DNA damage repair (DDR) allowing treatment of various cancers

Regarding Ossianix , it's portfolio is taking a break whilst it targets a treatment for (SARS-CoV-2). Plus it's lead product is now Parkinsons Disease.


Nov 09, 2020,
About Ossianix
Ossianix is an antibody engineering company that utilizes single domain antibodies (VNAR) from the shark to develop novel biopharmaceuticals for a number of therapeutic areas including CNS. The proprietary VNAR platform has allowe d the identification of highly potent BBB shuttles that target the transferrin receptor. The company's lead product is a BBB targeted agonist antibody to the TrkB receptor for Parkinson's disease.


I notice one of Ossianix targets for GBM (Glioblastoma Multiform) is check point indicator PD-L1 , there has not been much success with that target for Glioblastoma.


https://pubmed.ncbi.nlm.nih.gov/30777100/

Abstract

PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targetos PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint blockades have not achieved breakthroughs in treating glioblastoma because glioblastoma has a low immunogenic response and an immunosuppressive microenvironment caused by the precise crosstalk between cytokines and immune cells. A phase III clinical trial, Checkmate 143, reported that nivolumab, which targets PD-1, did not demonstrate survival benefits compared with bavacizumab in recurrent glioblastoma patients.

Their other target is EGFR v111

Epidermal growth factor receptor variant III (EGFR^vIII), only suitable in 28 to 30% of Glioblastoma patients as its only selectively expressed on Cancer Cells.

16 DEC 2019

EGFR^vIII: An Oncogene with Ambiguous Role.

10. Summary

Table2presents most important issues addressed in the article (except therapies in Table1). EGFR^vIIIprotein may be considered a suitable target in 28–30% of GB cases, as it is selectively expressed on cancer cells and structurally differs from wild-type receptor. Nevertheless, opinions on the role of EGFR^vIIIin GB biology are contradictory. This mutated receptor seems to play a key role in tumor cells, enhancing their proliferation, inhibiting apoptosis, or being considered a marker of CSCs. On the other hand, it is suggested that EGFR^vIIIis unnecessary for GB cells, especially at advanced stages of tumorigenesis, that may be considered a drawback in terms of therapeutic approaches directed against this mutated receptor. Despite many years of extensive research, EGFR^vIII-specific inhibitors have not been developed yet. There are also many controversies regarding antibodies designed to specifically detect this oncogenic variant, which in turn may be negatively correlated with the efficacy of CAR-T and other immunotherapy-based approaches. Many factors hinder glioblastoma treatment, including heterogeneity of EGFR^WT/EGFR^vIIIexpression, the impact of receptor signaling on various cellular processes, mechanisms of cells resistance to treatment, or the presence of cancer stem cell populations. Undoubtedly, anti-EGFR^vIIItherapies constitute the important area of research, but the structure, mechanism of action, and the biological role of EGFR^vIIIneed to be determined for their proper development. In particular, it is crucial to resolve whether EGFR^vIII-negative glioblastoma cells are dependent on EGFR^vIII-positive population or not.